We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




CRISPR-based Electrochemical Biosensor Detects Disease-related MicroRNAs

By LabMedica International staff writers
Posted on 03 Dec 2019
Print article
Image: Researchers introduced the first electrochemical CRISPR-based biosensor to help improve disease diagnostics (Photo courtesy of Richard Bruch, University of Freiburg)
Image: Researchers introduced the first electrochemical CRISPR-based biosensor to help improve disease diagnostics (Photo courtesy of Richard Bruch, University of Freiburg)
A microfluidic chip containing a CRISPR/Cas-based electrochemical biosensor has been introduced as a device for the rapid and precise analysis of the microRNAs involved in various disease states.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.

CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Recent computational efforts to identify new CRISPR systems uncovered a novel type of RNA targeting enzyme, Cas13. The diverse Cas13 family contains at least four known subtypes, including Cas13a (formerly C2c2), Cas13b, Cas13c, and Cas13d. Cas13a was shown to bind and cleave RNA, protecting bacteria from RNA phages and serving as a powerful platform for RNA manipulation. It was suggested that Cas13a could function as part of a versatile, RNA-guided RNA-targeting CRISPR/Cas system holding great potential for precise, robust, and scalable RNA-guided RNA-targeting applications.

Investigators at the University of Freiburg (Germany) exploited the features of Cas13a by using it to power a microfluidic, integrated electrochemical biosensor for the on‐site detection of microRNAs. An RNA-containing serum sample was placed in the sensor. If it contained the target RNA, this molecule combined with a protein complex in the solution and activated the Cas cleavage enzyme. Following activation, the enzyme cleaved reporter RNAs that were attached to signaling molecules, generating an electrical current, which was measured electrochemically. This change indicated whether the target miRNA was present in the sample. If the target microRNA was not present, no current was generated.

The investigators showed that by employing this unique combination of agents, the quantification of the potential microRNA tumor markers miR‐19b and miR‐20a was achieved without nucleic acid amplification. The system required less than 0.6 microliters of sample, had a readout time of nine minutes, and an overall process time of less than four hours. Furthermore, the feasibility of the biosensor platform to detect miR‐19b in serum samples from children suffering from brain cancer, was demonstrated.

“Our electrochemical biosensor is five to 10 times more sensitive than other applications which use CRISPR/Cas for RNA analysis,” said contributing author Dr. Can Dincer, a research group leader in the department of microsystems engineering at the University of Freiburg. “What is special about our system is that it works without the replication of miRNA, because in that case, specialized devices and chemicals would be required. That makes our system low-cost and considerably faster than other techniques or methods.”

The CRISPR-based biosensor was described in the October 30, 2019, online edition of the journal Advanced Materials.

Related Links:
University of Freiburg

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.